Gastric Cancer Liver Metastasis Cohort of China

Neoplasm Metastasis Clinical Trial

— RECORD  

Official title:

Retrospective Multi-institutional Cohort Study of Gastric Cancer Liver Metastasis in Real-world Data of China

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04574245
• Other study ID #: S2020-381
• Status: Active, not recruiting
• Start date: January 1, 2010
• Est. completion date: December 31, 2022

Study information

• Verified date: October 2022
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This multi-institutional retrospective cohort study aimed to describe and analyze the overall clinical characteristics, therapeutic status and prognosis pattern of gastric cancer liver metastasis (GCLM) in China.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3000
• Est. completion date: December 31, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Gastric cancer liver metastases cases aged over 18 years old;
• Primary gastric carcinoma (including different histopathological types) confirmed by biopsy or surgery (pre-, intra- or post- treatment);
• In hospital cases between 2020/01/01 to 2019/12/3.

Exclusion Criteria:

• Poor compliance to treatment or lost to follow-up;
• Gross loss of clinical data.

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Neoplasms
• Stomach Neoplasms

Intervention

Procedure:
• Gastrectomy; Hepatectomy

Locations

Country	Name	City	State
China	General Surgery Institute, China PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Zhang K, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol. 2020 Feb 20;12:1758835920904803. doi: 10.1177/1758835920904803. eCollection 2020. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1-year overall survival	The proportion (%) of gastric cancer liver metastasis patients that survived beyond one-year follow-up period.	2011/01/01-2020/12/31
Primary	3-year overall survival	The proportion (%) of gastric cancer liver metastasis patients that survived beyond three-year follow-up period.	2011/01/01-2021/12/31
Primary	5-year overall survival	The proportion (%) of gastric cancer liver metastasis patients that survived beyond five-year follow-up period.	2011/01/01-2021/12/31
Secondary	The incidence of gastric cancer liver metastasis cases	The rate of gastric cancer liver metastasis cases divided by all gastric cancer cases in the study period.	2010/01/01-2019/12/31
Secondary	The proportion for synchronous and metachronous liver metastases cases	The proportion (%) of synchronous or metachronous gastric cancer liver metastases cases in all gastric cancer cases	2010/01/01-2019/12/31
Secondary	The survival of patients that recieved different therapeutic methods	The proportion (%) of patients under different therapies that survived beyond specific follow-up period.	2010/01/01-2019/12/31
Secondary	The prognostic predictive value for patients with different C-GCLM classification	The proportion (%) of patients of different classification that survived beyond specific follow-up period.	2010/01/01-2019/12/31